Form 4: Ionis Pharmaceuticals Executive Granted Stock Options
SEC Form 4
Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, received 22,000 non-qualified stock options on January 2, 2025.
Summary
- On January 2, 2025, Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, was granted 22,000 non-qualified stock options.
- The exercise price of these options is $34.69.
- The options vest over a period of 4 years, with 25% vesting on January 2, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter.
- The options expire on January 1, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
NA
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the executive to improve company performance.
- Employees may see this as a standard practice for executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock option grant. |
| 01/02/2026 | Date when 25% of the stock options vest. |
| 01/01/2035 | Expiration date of the stock options. |
| 01/03/2025 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.